worldwid
acut
respiratori
infect
ari
constitut
lead
caus
acut
ill
respons
nearli
million
death
everi
year
mostli
young
children
infant
develop
countri
main
infecti
agent
respons
ari
includ
influenza
viru
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
streptococcu
pneumonia
haemophilu
influenza
effect
vaccin
influenza
h
influenza
type
b
hib
pneumonia
infect
avail
sever
year
vaccin
avail
present
ill
caus
rsv
metapneumoviru
three
novel
coronavirus
addit
threat
constitut
multipl
outbreak
avian
influenza
last
year
urgent
call
develop
new
influenza
vaccin
broader
spectrum
efficaci
could
provid
immun
avian
influenza
viru
pandem
articl
review
state
art
vaccin
r
ari
attempt
address
basic
public
health
question
acut
respiratori
infect
ari
continu
lead
caus
acut
ill
worldwid
wherea
upper
respiratori
infect
uri
common
seldom
lifethreaten
lower
respiratori
infect
lri
respons
sever
ill
pneumonia
bronchiol
lead
contributor
nearli
million
death
caus
year
respiratori
diseas
death
occur
children
develop
countri
particularli
live
africa
southeast
asia
popul
greatest
risk
develop
fatal
respiratori
infect
young
elderli
immunocompromis
overlap
clinic
manifest
differ
syndrom
constitut
lri
difficulti
establish
precis
bacteriolog
viral
etiolog
frequent
occurr
concurr
infect
one
pathogen
includ
measl
make
estim
syndromespecif
pathogenspecif
diseas
burden
particularli
difficult
howev
substanti
reduct
lri
mortal
observ
studi
sever
develop
countri
implement
simpl
case
manag
base
earli
detect
provis
antibiot
children
lri
suggest
bacteri
pneumonia
contribut
major
death
popul
addit
nosocomi
hospitalacquir
pneumonia
major
infecti
problem
pneumonia
second
common
type
nosocomi
infect
associ
case
fatal
rate
main
etiolog
agent
respons
ari
children
includ
streptococcu
pneumonia
haemophilu
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
elderli
influenzarel
pneumonia
remain
lead
caus
infecti
diseaserel
death
sever
novel
agent
associ
lri
discov
past
year
includ
metapneumoviru
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
human
pneumoniaassoci
coronavirus
measl
adenoviru
rhinovirus
also
frequent
caus
respiratori
diseas
addit
member
herpesviru
famili
includ
herp
simplex
cytomegaloviru
varicellazost
viru
epsteinbarr
viru
human
herp
viru
type
also
associ
respiratori
diseas
estim
one
five
hospit
occur
year
usa
lri
children
less
year
age
due
rsv
influenza
viru
avail
data
also
suggest
dual
infect
virus
bacteri
pathogen
quit
common
especi
develop
countri
studi
papua
new
guinea
bacteria
isol
blood
cultur
lung
aspir
twothird
children
viral
ari
recent
efficaci
trial
pneumococc
vaccin
south
africa
show
reduct
hospit
virusassoci
pneumonia
vaccin
group
suggest
children
dual
infect
although
exact
relationship
viral
bacteri
infect
case
establish
dual
infect
seem
increas
sever
diseas
result
higher
mortal
today
loom
new
threat
seem
avian
influenza
multipl
independ
outbreak
last
year
involv
sever
differ
viru
strain
asia
north
america
netherland
dire
warn
potenti
flu
pandem
imposs
predict
viru
go
caus
go
happen
prepar
potenti
event
go
mani
part
world
use
techniqu
revers
genet
possibl
develop
vaccin
potenti
pandem
influenza
viru
strain
avian
strain
moreov
number
influenza
subunit
dna
vaccin
candid
variou
stage
develop
bear
hope
induc
broad
spectrum
immun
multipl
strain
influenza
viru
live
attenu
parainfluenza
viru
piv
vaccin
develop
deliveri
intranas
rout
human
strain
bovin
isol
close
relat
antigen
human
first
vaccin
candid
found
overattenu
prompt
work
chimer
bovinehuman
candid
vaccin
similarli
develop
live
attenu
rsv
vaccin
could
deliv
intranas
met
difficulti
overor
underattenu
viru
limit
genet
stabil
number
subunit
vaccin
base
f
g
protein
rsv
develop
keep
mind
studi
shown
children
vaccin
inactiv
rsv
vaccin
suffer
sever
diseas
subsequ
exposur
viru
larg
number
candid
vaccin
sar
also
develop
includ
whole
inactiv
viru
vaccin
prepar
live
virusvector
recombin
vaccin
express
sarscov
protein
dna
vaccin
well
subunit
vaccin
vaccin
howev
face
uncertainti
due
lack
reliabl
anim
model
test
uncertainti
occurr
new
outbreak
diseas
protect
immun
pneumoniaeinduc
ill
confer
typespecif
anticapsular
polysaccharid
ps
antibodi
sever
vaccin
manufactur
develop
pneumococc
conjug
vaccin
pneumonia
ps
coval
coupl
protein
carrier
introduct
pneumococcu
conjug
vaccin
earli
usa
result
dramat
declin
rate
invas
pneumococc
diseas
unfortun
current
licens
conjug
vaccin
contain
serotyp
caus
sever
diseas
develop
countri
recent
publish
result
phase
iii
clinic
trial
vaccin
gambia
show
efficaci
vaccin
type
invas
diseas
reduct
mortal
vaccin
group
give
hope
introduct
pneumococcu
conjug
vaccin
dramat
effect
child
surviv
develop
countri
newer
approach
base
pneumococc
protein
preclin
earli
clinic
stage
develop
conjug
vaccin
haemophilu
influenza
type
b
highli
effect
prevent
hib
induc
diseas
unfortun
vaccin
remain
expens
world
poorer
nation
would
benefit
introduc
nation
immun
system
global
allianc
vaccin
immun
gavi
offer
support
hib
vaccin
introduct
develop
countri
sinc
articl
review
ongo
develop
futur
vaccin
combat
variou
ill
haemophilu
influenza
type
b
hib
current
respons
million
seriou
ill
nearli
death
per
year
chiefli
mening
pneumonia
almost
victim
children
less
year
age
convent
studi
burden
hib
diseas
focus
mening
invas
diseas
studi
shown
annual
incid
rate
laboratoryconfirm
hib
mening
case
per
children
age
less
year
industri
countri
prospect
populationbas
studi
conduct
countri
classifi
develop
least
develop
subsaharan
african
middl
east
latin
america
pacif
island
includ
philippin
incid
rate
hib
mening
compar
higher
north
america
europ
contrast
incid
rate
found
substanti
lower
asia
eastern
europ
howev
studi
reli
microbiolog
identif
hib
may
underestim
actual
diseas
burden
burden
hib
pneumonia
like
higher
invas
diseas
remain
difficult
defin
sinc
exist
techniqu
establish
bacteri
etiolog
lack
sensit
specif
review
sever
studi
asia
africa
oceania
conduct
sinc
show
pneumonia
h
influenza
account
bacteri
pneumonia
respect
sever
studi
serotyp
perform
type
b
account
pneumonia
case
field
trial
hib
conjug
vaccin
demonstr
reduct
pneumonia
follow
vaccin
gambia
reduct
hospit
pneumonia
chile
recent
estim
brazil
show
reduct
radiolog
pneumonia
follow
hib
vaccin
hand
prospect
random
control
trial
hib
vaccin
lombock
indonesia
found
reduct
radiolog
pneumonia
reduct
clinic
pneumonia
suggest
low
frequenc
hib
pneumonia
part
asia
h
influenza
small
fastidi
bacterium
requir
hemin
x
factor
nicotinamid
adenin
dinucleotid
nad
v
factor
growth
explain
grow
regular
blood
agar
chocol
agar
made
heat
blood
red
blood
cell
lyse
releas
v
factor
base
differ
composit
polysaccharid
capsul
six
serotyp
identifi
af
serotyp
b
hib
caus
invas
infect
addit
bacteria
classifi
six
differ
biotyp
ivi
nonencapsul
strain
h
influenza
seldom
caus
invas
diseas
import
caus
pneumonia
current
three
conjug
hib
vaccin
exist
differ
natur
carrier
protein
size
amount
capsular
ps
conjug
method
hboc
whose
carrier
mutant
diphtheria
toxin
prpt
use
tetanu
toxoid
carrier
prpomp
whose
carrier
meningococc
outer
membran
protein
although
dynam
immun
respons
elicit
vaccin
may
vari
respons
follow
primari
seri
vaccin
compar
efficaci
vaccin
prevent
mening
also
pneumonia
well
document
sever
studi
industri
countri
well
gambia
studi
demonstr
greater
protect
efficaci
laboratoryconfirm
invas
diseas
irrespect
choic
vaccin
consequ
hib
vaccin
includ
nation
immun
programm
industri
countri
result
nearelimin
invas
hib
diseas
thank
fact
mucos
immun
vaccine
result
decreas
transmiss
pathogen
popul
avail
data
develop
countri
also
show
similar
herd
immun
effect
possibl
vaccin
newborn
matern
immun
also
studi
although
hib
vaccin
highli
effect
vaccin
despit
success
vaccin
industri
countri
cost
unfortun
remain
high
world
poorest
nation
vaccin
cost
nearli
seven
time
total
cost
routin
childhood
vaccin
togeth
sustain
use
threaten
develop
countri
introduc
immun
programm
definit
progress
made
introduct
hib
vaccin
develop
countri
establish
global
allianc
vaccin
immun
gavi
although
signific
hurdl
still
remain
hib
vaccin
task
forc
commiss
gavi
conclud
countri
decis
introduc
hib
vaccin
lack
care
analysi
review
local
burden
diseas
accur
cost
benefit
analysi
hib
vaccin
introduct
subsequ
gavi
approv
establish
hib
initi
support
countri
wish
sustain
hib
vaccin
immun
well
countri
wish
explor
whether
introduct
vaccin
consid
prioriti
immun
programm
burden
influenza
usa
current
estim
million
case
per
year
lead
hospit
death
figur
extrapol
rest
world
averag
global
burden
interpandem
influenza
may
order
billion
case
includ
million
case
sever
ill
death
annual
epidem
outbreak
influenza
occur
differ
season
pattern
depend
region
world
temper
climat
zone
season
epidem
typic
begin
late
fall
peak
midto
late
winter
tropic
zone
season
pattern
appear
less
pronounc
yearround
isol
viru
industri
countri
annual
influenza
epidem
infect
popul
season
caus
febril
ill
rang
sever
mild
debilit
lead
instanc
hospit
even
caus
death
latter
mostli
occur
consequ
primari
fulmin
influenza
viru
pneumonia
secondari
respiratori
bacteri
infect
facilit
underli
pulmonari
cardiopulmonari
patholog
risk
develop
seriou
complic
aggrav
young
elderli
data
collect
michigan
usa
japan
indic
mass
vaccin
schoolag
children
correl
reduc
rate
respiratori
ill
age
group
suggest
largescal
immun
childhood
could
favor
affect
influenza
epidem
repetit
occurr
yearli
influenza
epidem
maintain
ongo
process
antigen
drift
result
accumul
point
mutat
gene
encod
two
viral
surfac
protein
hemagglutinin
ha
neuraminidas
na
lead
constant
emerg
new
viru
strain
littl
preexist
immun
popul
unpredict
interv
due
segment
natur
influenza
viru
genom
virus
also
acquir
new
gene
avian
anim
influenza
viru
process
believ
occur
readili
pig
anim
infect
avian
well
human
virus
coinfect
pig
result
emerg
viru
complet
new
glycoprotein
subtyp
event
refer
antigen
shift
recombin
viru
infect
human
popul
succe
effici
spread
persontoperson
worldwid
epidem
known
pandem
occur
three
pandem
occur
last
centuri
sever
infect
approxim
world
popul
kill
impress
million
peopl
particularli
prime
live
pandem
depress
popul
growth
follow
year
one
last
outbreak
influenza
high
mortal
pandem
potenti
occur
new
influenza
viru
avian
viru
ha
glycoprotein
emerg
hong
kong
china
kill
affect
patient
mainli
young
adult
fortun
viru
abl
spread
persontoperson
possibl
stop
outbreak
massiv
cull
poultri
anoth
strain
isol
sever
countri
asia
includ
vietnam
thailand
kill
altogeth
patient
diagnos
viru
recent
outbreak
coincid
major
epizoot
avian
flu
south
east
asia
due
highli
pathogen
viru
strain
kill
domest
poultri
except
duck
also
wild
bird
gees
flamingo
speci
aquat
bird
viru
also
pathogen
ferret
cat
tiger
cat
infect
viru
respiratori
rout
feed
virusinfect
bird
fear
viru
could
gain
capac
spread
human
popul
chang
receptorbind
specif
mutat
reassort
lead
new
pandem
far
humantohuman
transmiss
document
certitud
although
increas
number
report
famili
cluster
vietnam
might
signal
humantohuman
transmiss
find
sever
poultri
worker
carri
antibodi
viru
outbreak
hong
kong
well
outbreak
japan
point
exist
mild
asymptomat
avian
flu
infect
human
concert
action
establish
true
extent
spread
viru
still
lack
meanwhil
fresh
bird
outbreak
report
indonesia
fear
north
korea
might
infect
well
avian
influenza
virus
occasion
caus
human
outbreak
strain
hong
kong
strain
netherland
caus
confirm
human
case
conjunct
one
death
strain
north
america
usa
impact
new
pandem
assum
would
similar
magnitud
pandem
like
pandem
project
million
outpati
visit
hospit
death
extrapol
figur
world
popul
gross
estim
impact
next
pandem
call
billion
case
flu
million
case
sever
ill
million
death
worldwid
econom
cost
pandem
estim
us
billion
industri
countri
combin
includ
direct
medic
cost
lost
product
result
diseas
death
influenza
virus
envelop
virus
segment
genom
made
eight
singlestrand
neg
rna
segment
encod
one
viral
protein
eg
ha
na
np
influenza
virus
belong
famili
orthomyxovirida
divid
three
genera
influenzaviru
influenzaviru
b
influenzaviru
c
base
antigen
differ
two
structur
protein
matrix
protein
nucleoprotein
np
influenza
virus
divid
subtyp
accord
antigen
major
envelop
glycoprotein
ha
na
fifteen
ha
subtyp
nine
na
subtyp
identifi
far
virus
subtyp
current
circul
human
popul
influenza
virus
also
infect
poultri
aquat
bird
pig
hors
sea
mammal
aquat
bird
viru
multipli
gut
usual
asymptomat
infect
excret
viru
fece
thu
serv
natur
viru
reservoir
potenti
sourc
new
gene
pandem
influenza
virus
swap
genom
segment
lead
emerg
new
reassort
progeni
strain
mix
genotyp
readili
occur
pig
pig
complet
set
sialyl
receptor
avian
swine
human
influenza
viru
strain
ha
present
surfac
flu
virion
form
precursor
must
undergo
proteolyt
cleavag
gener
function
subunit
bear
receptorbind
site
neutral
epitop
respons
fusion
viral
envelop
hostcel
membran
bind
virion
sialic
acidcontain
cell
receptor
virusreceptor
complex
endocytos
endosom
whose
acidif
trigger
conform
rearrang
viral
ha
fusion
peptid
n
terminu
polypeptid
insert
target
cell
membran
fold
coil
coil
bring
viral
cell
membran
close
contact
fusion
occur
classic
avian
viru
strain
trypsinlik
cleavag
site
henc
tropism
gastrointestin
tract
contrast
highli
virul
avian
strain
strain
vietnam
thailand
acquir
spontan
mutat
ubiquit
furinlik
cleavag
site
allow
multipli
mani
tissu
includ
respiratori
tract
na
neuraminidas
cleav
sialic
acid
residu
promot
releas
matur
viru
particl
infect
cell
facilit
dispers
mucu
layer
influenza
antivir
drug
includ
amantadin
rimantadin
devoid
effect
viru
strain
zanamivir
renza
osaltamivir
tamiflu
block
egress
progeni
viru
particl
infect
cell
inhibit
viral
neuraminidas
activ
activ
virus
drug
howev
avail
limit
suppli
current
avail
influenza
vaccin
made
inactiv
detergentsplit
influenza
viru
grown
allanto
caviti
embryon
chicken
egg
vaccin
effect
prevent
influenzarel
ill
high
benefittocost
ratio
term
prevent
hospit
death
shown
numer
studi
vaccin
elderli
individu
high
risk
sever
outcom
influenza
estim
global
billion
peopl
high
risk
sever
influenza
outcom
million
elderli
year
age
million
infant
sever
hundr
million
children
adult
underli
chronic
health
problem
last
number
still
remain
unknown
although
estim
industri
countri
around
total
popul
chronic
underli
respiratori
diseas
includ
asthma
addit
million
health
care
worker
immun
prevent
spread
diseas
highrisk
popul
time
world
total
vaccin
product
capac
limit
million
dose
realist
suffic
cover
global
highrisk
popul
therefor
quit
evid
global
infrastructur
would
abl
handl
time
manufactur
distribut
deliveri
pandem
influenza
vaccin
likelihood
would
given
twodos
regimen
peopl
previou
exposur
viru
antigen
one
solut
problem
would
lower
quantiti
antigen
per
dose
add
adjuv
vaccin
need
test
clinic
trial
use
iscom
immunostimul
complex
vaccin
acceler
antibodi
respons
human
coincid
prolif
tcell
respons
anoth
solut
would
improv
current
vaccin
product
technolog
eggderiv
vaccin
sever
pharmaceut
compani
embark
project
develop
cellcultur
vaccin
could
help
overcom
current
vaccin
product
bottleneck
limit
avail
specif
pathogenfre
egg
suppli
time
constraint
furthermor
would
improv
possibl
upscal
vaccin
product
capac
face
pandem
influenza
viru
adapt
grow
varieti
mammalian
cell
line
includ
vero
madindarbi
canin
kidney
mdck
cell
line
crucel
holland
partner
sanofipasteur
franc
develop
largescal
cellcultur
method
use
human
cell
pandem
vaccin
annual
influenza
vaccin
clinic
trial
expect
start
summer
possibl
develop
vaccin
potenti
pandem
influenza
viru
strain
avian
strain
use
techniqu
revers
genet
process
requir
first
mutagen
cleavag
site
new
strain
attenu
virul
transfer
ha
na
genom
segment
appropri
influenza
viru
master
strain
strain
adapt
grow
vero
cell
thu
gener
within
week
reassort
viru
antigen
specif
pandem
strain
growth
characterist
master
strain
includ
adapt
cell
cultur
assess
dosag
reversegenet
vaccin
vietnam
viru
clinic
trial
conduct
nih
bethesda
usa
use
chicken
egggrown
vaccin
lot
prepar
chiron
sanofipasteur
countri
follow
path
soon
embark
test
immunogen
low
dose
alumadjuv
vaccin
intellectu
properti
liabil
issu
consid
obstacl
industri
develop
reversegeneticsbas
vaccin
count
fact
virus
consid
genet
modifi
organ
need
special
clearanc
countri
formul
inactiv
influenza
vaccin
mucos
deliveri
develop
includ
iscomatrix
adjuv
vaccin
powder
vaccin
develop
avian
viru
strain
texasbas
delsit
biotechnolog
note
inactiv
vaccin
asia
viru
strain
develop
veterinari
medicin
use
avian
influenzaviru
strain
less
pathogen
grow
high
titer
embryon
chicken
egg
inactiv
provid
protect
viru
challeng
poultri
anoth
approach
influenza
vaccin
develop
coldadapt
ca
viru
strain
grow
well
primari
chick
kidney
cell
embryon
egg
c
reduc
replic
titer
c
show
attenu
behavior
ferret
cold
adapt
found
reliabl
effici
procedur
deriv
live
attenu
influenza
viru
vaccin
human
process
genet
reassort
transfer
six
intern
gene
stabl
attenu
ca
master
donor
strain
influenza
viru
influenza
b
viru
new
prevail
wildtyp
epidem
strain
use
gener
attenu
coldreassort
vaccin
proper
level
attenu
immunogen
human
genet
stabil
low
absent
transmiss
vaccine
contact
trival
live
ca
vaccin
flumist
develop
along
line
medimmun
wyeth
intranas
spray
deliveri
vaccin
proven
highli
efficaci
phase
iii
trial
show
overal
protect
rate
studi
children
includ
protect
antigen
variant
circul
region
second
year
efficaci
children
year
age
inde
found
superior
inactiv
vaccin
vaccin
licens
usa
vaccin
person
year
age
view
side
effect
younger
children
wheez
nasal
congest
absenc
data
elderli
vaccin
safe
effect
show
remark
genet
stabil
kept
c
new
heatstabl
version
vaccin
recent
develop
shown
good
efficaci
clinic
trial
asia
europ
includ
young
children
applic
european
licensur
pend
medimmun
anoth
coldadapt
master
viru
strain
develop
institut
appli
microbiolog
austria
growth
wild
influenza
viru
vero
cell
c
live
vaccin
base
master
viru
strain
safe
well
toler
immunogen
intranas
immun
young
adult
volunt
biodiem
limit
australia
merck
develop
yet
anoth
live
attenu
influenza
vaccin
deliv
nasal
spray
vector
scientif
center
russia
focus
coldadapt
live
attenu
viru
grown
mdck
cell
microcarri
bead
serumfre
medium
vaccin
advanc
preclin
develop
stage
number
influenza
subunit
dna
vaccin
candid
variou
stage
develop
berna
biotech
commerci
influenza
vaccin
formul
virosom
surfac
spike
three
current
circul
influenza
viru
strain
insert
vesicl
membran
three
correspond
virosom
type
nasal
formul
vaccin
howev
recent
withdrawn
market
due
undesir
neurolog
side
effect
bell
palsi
link
presenc
e
coli
labil
toxin
lt
use
adjuv
like
consequ
bind
b
subunit
lt
gangliosid
neuron
tissu
associ
olfactori
tract
protein
scienc
corp
connecticut
develop
subunit
vaccin
use
recombin
ha
protein
produc
serumfre
insect
cell
cultur
baculoviru
vector
vaccin
success
test
phase
ii
trial
volunt
induc
good
antiha
antibodi
respons
phase
iiiii
trial
volunt
underway
person
commun
yeda
bionvax
isra
r
compani
develop
synthet
peptid
influenza
vaccin
nasal
administr
vaccin
shown
protect
efficaci
human
mice
plan
enter
clinic
trial
epiderm
dna
influenza
vaccin
develop
test
human
powderject
vaccin
found
safe
immunogen
subject
prevaccin
antibodi
influenza
viru
drape
macklin
et
al
press
dna
vaccin
influenza
still
earli
stage
develop
due
poor
immunogen
result
nake
dna
human
final
recombin
particul
vaccin
engin
genet
fuse
copi
influenza
viru
transmembran
protein
hepat
b
core
antigen
hbc
hbc
fusion
protein
spontan
assembl
viruslik
particl
vlp
provid
complet
protect
potenti
lethal
influenza
viru
challeng
mice
similarli
peptid
conjug
neisseria
meningitidi
outer
membran
protein
complex
ompc
recent
evalu
anim
model
includ
monkey
highli
conserv
transmembran
protein
virion
approach
might
thu
serv
basi
univers
influenza
vaccin
broad
spectrum
protect
activ
parainfluenza
virus
caus
spectrum
respiratori
ill
uri
complic
otiti
media
lri
requir
hospit
children
infect
parainfluenza
viru
type
age
year
parainfluenza
viru
type
age
year
infect
second
rsv
infect
viral
caus
seriou
ari
young
children
pneumonia
bronchiol
infect
occur
primarili
first
six
month
life
case
rsv
infect
croup
signatur
clinic
manifest
infect
parainfluenza
virus
especi
chief
caus
hospit
parainfluenza
infect
children
year
age
howev
syndrom
rel
less
frequent
develop
countri
proport
hospit
associ
piv
infect
vari
wide
hospitalbas
studi
consequ
annual
estim
rate
hospit
fall
within
broad
rang
estim
account
annual
hospit
usa
hospit
hospit
along
rsv
parainfluenza
virus
also
lead
caus
hospit
adult
communityacquir
respiratori
diseas
season
pattern
infect
curious
interact
caus
largest
defin
outbreak
mark
sharp
biennial
rise
case
croup
autumn
oddnumb
year
outbreak
infect
though
errat
usual
follow
type
outbreak
outbreak
infect
occur
yearli
mainli
spring
summer
last
longer
outbreak
type
although
describ
caus
lri
develop
countri
diseas
burden
accur
quantifi
countri
parainfluenza
virus
belong
famili
paramyxovirida
subfamili
paramyxovirina
subdivid
three
genera
paramyxoviru
sendai
viru
rubulaviru
mump
viru
morbilliviru
measl
viru
envelop
virus
neg
strand
nucleotidelong
nonseg
rna
genom
encod
two
envelop
glycoprotein
hemagglutininneuraminidas
hn
fusion
protein
f
cleav
fusion
activ
disulfidelink
subunit
matrix
protein
nucleocapsid
protein
n
sever
nonstructur
protein
includ
viral
replicas
l
hn
protein
mediat
primari
attach
virion
target
cell
f
protein
promot
fusion
viru
envelop
cell
membran
membran
fusion
initi
insert
cell
membran
viral
fusion
peptid
locat
n
terminu
subunit
two
heptad
repeat
region
one
immedi
ctermin
fusion
peptid
adjac
transmembran
domain
fold
trimer
helic
coiledcoil
sixhelix
bundl
bring
viru
envelop
close
contact
cell
membran
similar
mechan
report
number
viral
fusion
protein
includ
paramyxovirus
rsv
hiv
env
glycoprotein
lowph
form
influenza
viru
ha
protein
review
see
live
attenu
parainfluenza
viru
vaccin
develop
human
bovin
strain
deliveri
intranas
rout
candid
vaccin
abl
replic
induc
protect
immun
respons
young
infant
presenc
matern
acquir
antibodi
achiev
appropri
balanc
attenu
immunogen
howev
major
obstacl
develop
vaccin
two
attenu
strain
studi
one
ts
human
strain
select
passag
viru
african
green
monkey
cell
low
temperatur
bovin
strain
close
relat
antigen
human
protect
monkey
challeng
human
replic
poorli
human
bovin
evalu
phase
iii
trial
rsv
seroposit
seroneg
children
young
infant
candid
found
overattenu
seroposit
children
immunogen
seroneg
children
infant
although
magnitud
antihn
respons
lower
children
receiv
bovin
vaccin
prompt
engin
chimer
bovinehuman
candid
vaccin
contain
human
f
hn
gene
intern
gene
bovin
one
chimer
virus
human
human
nucleocapsid
n
gene
replac
bovin
counterpart
viru
found
attenu
protect
nonhuman
primat
phase
clinic
trial
stage
chimer
bovin
express
f
hn
protein
human
use
backbon
f
f
g
orf
rsv
rsv
b
insert
provid
bival
candid
vaccin
rsv
infect
young
infant
attempt
also
made
develop
vaccin
sendai
viru
murin
found
protect
african
green
monkey
human
challeng
seem
suffici
attenu
use
jennerian
vaccin
human
infant
attenu
chimer
virus
contain
intern
gene
f
hn
gene
either
test
hamster
addit
berna
biotech
develop
virosom
formul
vaccin
rsv
import
caus
sever
lri
infant
young
children
worldwid
rsv
diseas
spectrum
includ
wide
array
respiratori
diseas
rang
rhiniti
otiti
media
pneumonia
bronchiol
latter
two
diseas
associ
substanti
morbid
mortal
human
known
reservoir
rsv
spread
viru
contamin
nasal
secret
occur
via
larg
respiratori
droplet
close
contact
infect
individu
contamin
surfac
requir
transmiss
rsv
persist
sever
hour
toy
object
explain
high
rate
nosocomi
rsv
infect
particularli
pediatr
ward
temper
climat
rsv
well
document
caus
yearli
winter
epidem
acut
lri
includ
bronchiol
pneumonia
industri
countri
nearli
children
year
age
infect
rsv
estim
respons
hospit
death
annual
usa
incid
rate
rsvassoci
lri
otherwis
healthi
children
calcul
per
childyear
first
two
year
life
per
childyear
infant
less
month
old
risk
hospit
per
childyear
per
childyear
first
six
month
life
incid
higher
children
cardiopulmonari
diseas
preterm
infant
constitut
almost
half
rsvrelat
hospit
admiss
usa
uk
estim
unspecifi
bronchiol
unspecifi
pneumonia
admiss
rsvrelat
total
annual
incid
hospit
admiss
attribut
rsv
countri
children
less
year
age
children
year
old
figur
avail
industri
countri
global
annual
infect
figur
rsv
estim
around
million
mortal
could
high
children
experi
sever
lri
caus
rsv
increas
incid
wheez
asthma
later
life
studi
serv
basi
anticip
widespread
use
rsv
vaccin
industri
countri
cost
care
patient
sever
lri
sequela
substanti
rsv
also
increasingli
recogn
import
caus
morbid
influenzalik
ill
elderli
populationbas
estim
incid
rsv
diseas
develop
countri
avail
although
exist
data
clearli
indic
also
viru
account
high
proport
lri
children
studi
colombia
brazil
india
thailand
show
rsv
caus
lri
case
children
year
age
proport
similar
observ
industri
countri
addit
accur
incid
rate
import
data
develop
countri
lack
sever
casefat
rate
rsv
infect
commun
level
median
age
first
infect
preliminari
data
communitybas
studi
suggest
median
age
first
infect
may
vari
commun
inform
import
vaccin
program
planner
consid
optim
schedul
vaccin
exampl
matern
immun
rsv
would
desir
strategi
adopt
rate
infect
first
two
month
life
found
high
anoth
confus
aspect
epidemiolog
rsv
infect
may
impact
vaccin
use
season
diseas
europ
north
america
rsv
diseas
occur
welldefin
season
outbreak
winter
spring
month
studi
develop
countri
temper
climat
argentina
pakistan
shown
similar
season
pattern
hand
studi
tropic
countri
often
report
increas
rsv
raini
season
constant
find
inde
mark
differ
season
occurr
rsv
diseas
report
geograph
contigu
region
eg
mozambiqu
south
africa
bangladesh
india
cultur
behavior
pattern
commun
might
affect
acquisit
spread
rsv
infect
clear
understand
local
epidemiolog
diseas
critic
implement
success
vaccin
develop
introduct
program
rsv
belong
famili
paramyxovirida
subfamili
pneumovirina
genu
pneumoviru
genom
rsv
nucleotidelong
singlestrand
negativesens
rna
molecul
whose
tight
associ
viral
n
protein
form
nucleocapsid
wrap
insid
viral
envelop
latter
contain
viral
encod
f
g
sh
glycoprotein
f
g
glycoprotein
two
compon
induc
rsv
neutral
antibodi
therefor
prime
import
vaccin
develop
sequenc
f
protein
respons
fusion
viru
envelop
target
cell
membran
see
section
highli
conserv
among
rsv
isol
contrast
g
protein
respons
viru
attach
rel
variabl
two
group
rsv
strain
describ
b
group
base
differ
antigen
g
glycoprotein
current
effort
direct
toward
develop
vaccin
incorpor
strain
group
direct
f
protein
promis
inhibitor
rsv
fusion
protein
abandon
partli
resist
mutat
map
f
gene
reminisc
phenomenon
observ
peptid
fusion
inhibitor
hiv
recent
report
individu
well
dual
infect
rsv
piv
could
prevent
short
interf
rna
sirna
instil
intranas
mous
might
pave
way
develop
new
strategi
antirsv
antipiv
therapi
human
develop
vaccin
prevent
rsv
infect
complic
fact
host
immun
respons
appear
play
role
pathogenesi
diseas
earli
studi
show
children
vaccin
formalininactiv
rsv
vaccin
suffer
sever
diseas
subsequ
exposur
viru
compar
unvaccin
control
earli
trial
result
hospit
vaccine
two
death
enhanc
sever
diseas
reproduc
anim
model
thought
result
inadequ
level
serum
neutral
antibodi
lack
local
immun
immun
complex
deposit
excess
induct
type
helper
tcelllik
immun
respons
pulmonari
eosinophilia
increas
product
cytokin
addit
natur
acquir
immun
rsv
neither
complet
durabl
recurr
infect
occur
frequent
studi
perform
houston
texa
found
children
acquir
rsv
infect
first
year
life
reinfect
second
year
reinfect
third
year
least
twothird
children
also
infect
first
two
year
life
older
children
adult
howev
usual
protect
rsvrelat
lri
suggest
protect
sever
diseas
develop
sever
success
infect
passiv
immun
rsvneutral
immun
globulin
human
monoclon
antibodi
given
prophylact
shown
prevent
rsv
infect
newborn
underli
cardiopulmonari
diseas
particularli
small
prematur
infant
demonstr
humor
antibodi
play
major
role
protect
diseas
gener
secretori
iga
serum
antibodi
appear
protect
infect
upper
lower
respiratori
tract
respect
tcell
immun
target
intern
viral
protein
appear
termin
viral
infect
although
live
attenu
vaccin
seem
prefer
immun
naiv
infant
inactiv
subunit
vaccin
latter
may
use
immun
elderli
highrisk
children
well
matern
immun
candid
subunit
vaccin
base
purifi
f
protein
found
safe
immunogen
healthi
adult
children
month
without
underli
pulmonari
diseas
well
elderli
subject
pregnant
women
phase
studi
conduct
women
week
pregnanc
vaccin
well
toler
induc
rsv
antif
antibodi
titer
persist
fourfold
higher
newborn
vaccin
mother
receiv
placebo
increas
frequenc
morbid
respiratori
diseas
observ
infant
vaccin
mother
matern
immun
use
pfp
subunit
vaccin
would
interest
strategi
protect
infant
younger
month
age
respond
poorli
vaccin
efficaci
subunit
vaccin
test
phase
iii
trial
children
year
age
cystic
fibrosi
vaccin
well
toler
induc
fourfold
increas
rsv
neutral
antibodi
titer
associ
signific
protect
lri
episod
compar
placebo
recipi
subunit
vaccin
develop
sanofipasteur
consist
copurifi
f
g
protein
rsv
test
healthi
adult
volunt
presenc
either
alum
polyphosphazen
pcpp
adjuv
neutral
antibodi
respons
rsv
rsv
b
detect
vaccine
titer
wane
year
suggest
annual
immun
vaccin
necessari
subunit
approach
also
investig
use
conserv
central
domain
g
protein
rsva
strain
whose
sequenc
rel
conserv
among
group
b
virus
recombin
vaccin
candid
develop
fuse
domain
albuminbind
region
bb
streptococc
protein
g
pierr
fabr
candid
vaccin
elicit
protect
immun
respons
anim
moder
immunogen
adult
human
volunt
clinic
develop
interrupt
due
appear
unexpect
side
effect
purpura
immun
volunt
anoth
rsv
candid
vaccin
synthet
peptid
conserv
region
g
protein
administ
intranas
either
alon
combin
cholera
toxin
protect
confer
mice
even
without
cholera
toxin
live
attenu
rsv
vaccin
could
deliv
respiratori
mucosa
intranas
immun
develop
decad
base
temperaturesensit
ts
coldadapt
ca
coldpassag
cp
mutant
strain
viru
difficulti
vaccin
aris
overor
underattenu
viru
limit
genet
stabil
attenu
live
rsv
strain
test
human
date
includ
cpt
mutant
attenu
adult
seroposit
children
caus
mild
moder
congest
upper
respiratori
tract
seroneg
infant
month
old
therefor
consid
insuffici
attenu
earli
infanc
recombin
rsv
vaccin
delet
mutat
nonessenti
gene
sh
cp
ts
mutat
essenti
gene
current
evalu
recombin
dna
technolog
also
provid
possibl
engin
chimer
viru
contain
gene
human
surfac
glycoprotein
f
nh
togeth
rsv
glycoprotein
f
g
bovin
genet
background
first
candid
vaccin
found
attenu
induc
immun
respons
human
rsv
rhesu
monkey
present
enter
clinic
trial
similarli
bovin
genom
engin
express
human
f
hn
protein
either
nativ
solubl
rsv
f
protein
result
recombin
induc
rsv
neutral
antibodi
protect
immun
rsv
challeng
african
green
monkey
bh
f
vaccin
present
test
safeti
efficaci
human
clinic
trial
bival
vaccin
protect
infant
rsv
infect
diseas
final
combin
liveattenu
vaccin
subunit
vaccin
also
consid
protect
adult
rsv
ill
although
preliminari
test
strategi
healthi
young
elderli
adult
inconclus
sever
acut
respiratori
syndrom
sar
sever
respiratori
ill
caus
newli
identifi
viru
sar
coronaviru
sarscov
diseas
emerg
southern
china
late
spread
spring
countri
within
asia
europ
north
america
epidem
final
came
stop
juli
strict
implement
quarantin
isol
procedur
intern
collabor
coordin
sar
character
fever
headach
cough
dyspnea
rapidli
progress
respiratori
distress
syndrom
patient
necessit
prolong
hospit
intens
care
mechan
ventil
multiphas
cours
infect
recurr
fever
diseas
appar
initi
improv
consist
tcell
lymphopenia
reminisc
fatal
multiphas
diseas
progress
acut
tcell
lymphopenia
observ
cat
infect
felin
infecti
periton
viru
fipv
anoth
coronaviru
accord
case
sar
identifi
worldwid
juli
patient
die
mortal
rate
sporad
minioutbreak
report
sinc
china
singapor
taiwan
two
link
laboratori
contamin
unappar
nonpneumon
infect
also
seem
quit
common
judg
seropreval
healthi
popul
blood
donor
medic
personnel
hong
kong
transmiss
thought
mostli
occur
respiratori
droplet
sever
instanc
nosocomi
infect
report
health
care
worker
high
risk
infect
although
evid
sarscov
emerg
nonhuman
sourc
anim
reservoir
yet
identifi
certainti
mask
palm
civet
cat
raccoon
dog
found
carrier
viru
chines
wild
anim
trader
show
high
seropreval
figur
especi
civet
cat
trader
sarscov
also
recov
rat
evid
natur
transmit
among
speci
viru
found
multipli
asymptomat
mice
cat
mildli
pathogen
monkey
ferret
mask
palm
civet
spite
limit
extens
rel
rapid
control
epidem
nation
author
highli
contagi
natur
diseas
high
fatal
rate
prompt
search
vaccin
sarscov
belong
newli
identifi
group
famili
coronavirida
envelop
virus
whose
envelop
character
crownlik
protein
spike
rna
genom
except
long
nucleotid
singlestrand
posit
rna
molecul
contain
open
read
frame
encod
replicas
molecul
protein
b
spike
protein
envelop
protein
e
membran
protein
nucleocapsid
protein
n
among
member
coronavirida
famili
human
coronavirus
agent
common
cold
felin
infecti
periton
viru
avian
infecti
bronchiti
viru
ibv
pig
transmiss
gastroenter
viru
tgev
two
novel
human
coronavirus
recent
isol
case
pneumonia
human
protein
virus
known
respons
induct
viru
neutral
antibodi
cov
speci
protein
cleav
proteas
yield
two
noncoval
associ
subunit
contain
receptorbind
site
form
membraneanchor
stalk
region
mediat
fusion
viral
cellular
membran
observ
influenzaviru
ha
paramyxoviru
f
hiv
env
glycoprotein
avail
data
suggest
howev
sarscov
spike
glycoprotein
cleav
two
moieti
contain
viral
receptorbind
site
neutral
epitop
ntermin
half
fusion
domain
two
heptad
repeat
well
anoth
neutral
epitop
ctermin
half
angiotensinconvert
enzym
receptor
recent
identifi
receptor
sarscov
protein
sarscov
prime
target
gener
neutral
antibodi
sarscov
develop
protect
humor
immun
human
neutral
monoclon
antibodi
target
protein
found
block
attach
viru
receptor
provid
remark
protect
mous
model
sarscov
infect
pave
way
eventu
use
passiv
serotherapi
provid
immedi
protect
infect
contact
medic
personnel
less
year
sar
first
appear
halfdozen
candid
vaccin
alreadi
develop
time
number
candid
vaccin
track
sever
whole
inactiv
viru
vaccin
prepar
one
alreadi
test
phase
clinic
trial
china
recombin
sarscov
glycoproteinmva
vaccin
found
elicit
potent
neutral
antibodi
respons
two
immun
rhesu
macaqu
protect
vaccin
monkey
virul
sarscov
challeng
intranas
rout
vaccin
face
uncertainti
howev
least
lack
reliabl
anim
model
test
undertak
clinic
trial
sar
vaccin
set
vanish
percept
potenti
risk
reemerg
diseas
yet
anoth
difficulti
final
uncertainti
possibl
immun
enhanc
phenomenon
observ
studi
vaccin
cat
felin
coronaviru
fipv
anim
vaccin
whole
inactiv
viru
vaccin
show
acceler
diseas
death
exposur
wild
type
viru
humor
respons
fipv
seem
protect
fact
lead
drastic
acceler
diseas
presum
due
antibodydepend
enhanc
target
cell
infect
via
fc
receptormedi
attach
virusantibodi
complex
control
infect
fipv
clearanc
thought
primarili
depend
cellmedi
immun
respons
fact
ferret
vaccin
experiment
mvasarscov
recombin
vaccin
suffer
strong
inflammatori
respons
liver
tissu
upon
sar
viru
challeng
cast
cautionari
note
immun
sar
vaccin
might
worsen
diseas
rather
prevent
base
avail
data
pneumonia
estim
caus
onethird
million
annual
child
death
follow
ari
especi
develop
countri
bacterium
one
import
bacteri
pathogen
infanc
earli
childhood
virtual
everi
child
colon
one
strain
pneumonia
becom
nasopharyng
carrier
first
year
life
carriag
common
occur
younger
age
children
develop
countri
mani
children
go
develop
one
episod
otiti
media
wherea
smaller
number
develop
seriou
invas
pneumococc
infect
bacterem
pneumonia
common
form
invas
pneumococc
diseas
next
common
pneumococc
mening
death
pneumonia
far
outnumb
death
mening
worldwid
usa
case
invas
pneumococc
diseas
character
febril
bacteremia
without
specif
local
incid
invas
pneumococc
diseas
less
infant
europ
rang
case
per
germani
netherland
spain
less
sever
frequent
form
pneumococc
diseas
includ
middleear
infect
sinus
recurr
bronchiti
thu
usa
alon
million
case
otiti
media
attribut
pneumococci
year
although
age
group
may
affect
highest
rate
pneumococc
diseas
occur
young
children
elderli
popul
addit
person
suffer
wide
rang
chronic
condit
immun
defici
increas
risk
europ
usa
pneumococc
pneumonia
account
least
case
communityacquir
pneumonia
admit
hospit
report
annual
incid
per
person
year
age
older
case
fatal
rate
howev
almost
data
rate
pneumococc
diseas
elderli
popul
develop
countri
pneumonia
underappreci
caus
nosocomi
pneumonia
hospit
ward
intens
care
unit
well
nurs
home
longterm
care
institut
pneumonia
also
lead
caus
nonepidem
childhood
mening
africa
region
develop
world
estim
children
develop
pneumococc
mening
either
die
remain
perman
disabl
children
infect
hivaid
time
like
contract
pneumococc
diseas
hiv
uninfect
children
pneumonia
gramposit
encapsul
diplococcu
base
differ
composit
polysaccharid
capsul
around
serotyp
identifi
capsul
essenti
virul
factor
major
pneumococc
diseas
infant
associ
small
number
serotyp
may
vari
region
time
current
data
suggest
common
serotyp
caus
least
invas
diseas
region
sever
virul
factor
describ
includ
pneumolysin
lead
pore
format
osmot
lysi
epitheli
cell
autolysin
pneumococc
surfac
protein
pspa
interfer
phagocytosi
immun
function
host
pneumococci
transmit
direct
contact
respiratori
secret
patient
healthi
carrier
although
transient
nasopharyng
colon
rather
diseas
normal
outcom
exposur
pneumococci
bacteri
spread
sinus
middl
ear
bacteremia
follow
penetr
mucos
layer
may
occur
person
suscept
involv
serotyp
secondari
infect
distant
site
eg
mening
pneumococc
resist
essenti
antimicrobi
penicillin
cephalosporin
macrolid
seriou
rapidli
increas
problem
worldwid
protect
immun
confer
typespecif
anticapsular
antibodi
although
serolog
correl
immun
poorli
defin
antibodi
sever
pneumococc
surfac
protein
includ
pspa
demonstr
confer
protect
anim
model
role
antibodi
human
yet
determin
current
licens
vaccin
polyval
polysaccharid
vaccin
contain
per
dose
g
purifi
capsular
ps
serotyp
pneumonia
togeth
account
case
seriou
pneumococc
diseas
western
industri
countri
rel
good
antibodi
respons
elicit
healthi
adult
within
week
follow
singl
intramuscular
subcutan
immun
immun
respons
howev
mediocr
children
age
less
year
immunocompromis
individu
hivaid
furthermor
ps
vaccin
induc
immunolog
memori
requir
subsequ
booster
respons
polyval
ps
vaccin
recommend
healthi
peopl
year
age
particularli
live
institut
random
control
trial
healthi
elderli
peopl
industri
countri
howev
fail
show
benefici
effect
vaccin
recommend
use
elderli
base
data
observ
studi
show
signific
protect
effect
invas
bacterem
pneumococc
diseas
pneumonia
follow
vaccin
pregnant
women
ps
vaccin
antip
antibodi
transfer
via
placenta
breast
milk
formal
demonstr
matern
vaccin
actual
protect
newborn
infant
pneumococc
diseas
still
lack
past
year
sever
vaccin
manufactur
develop
pneumococc
conjug
vaccin
number
pneumonia
ps
coval
coupl
protein
carrier
conjug
vaccin
elicit
higher
antibodi
level
effici
immun
respons
infant
young
children
immunodefici
person
ps
vaccin
well
signific
immunolog
memori
result
booster
antibodi
respons
subsequ
exposur
antigen
moreov
vaccin
suppress
nasopharyng
carriag
pathogen
reduc
bacteri
transmiss
commun
lead
herd
immun
add
consider
valu
implement
conjug
vaccin
immun
follow
ps
vaccin
boost
might
provid
foundat
lifelong
protect
pneumococc
diseas
doubleblind
phase
iii
studi
vaccin
prevnar
wyeth
conduct
northern
california
kaiser
permanent
medic
center
infant
case
invas
pneumonia
diseas
seen
studi
popul
control
group
repres
vaccin
efficaci
vaccin
found
efficaci
low
birthweight
preterm
infant
includ
studi
anoth
efficaci
trial
conjug
vaccin
usa
nativ
american
popul
show
efficaci
intenttotreat
invas
diseas
vaccin
also
show
reduct
radiolog
confirm
pneumonia
studi
california
two
differ
conjug
vaccin
formul
elicit
moder
protect
otiti
media
decreas
case
vaccinetyp
otiti
media
offset
increas
due
nonvaccinetyp
pneumonia
h
influenza
phenomenon
refer
replac
diseas
howev
vaccin
result
signific
reduct
otiti
media
requir
tympanostomi
tube
placement
trial
measur
effect
otiti
media
vaccin
h
influenza
protein
carrier
gsk
ongo
czech
republ
vaccin
may
provid
addit
protect
h
influenza
limit
replac
due
organ
result
trial
expect
shortli
introduct
conjug
vaccin
earli
usa
result
dramat
declin
rate
invas
pneumococc
diseas
signific
reduct
also
seen
unvaccin
individu
result
herd
immun
introduct
vaccin
also
shown
reduc
dispar
diseas
rate
black
white
children
though
per
cent
reduct
diseas
unvaccin
children
adult
lower
vaccin
children
number
case
invas
diseas
prevent
indirect
effect
vaccin
estim
greater
prevent
direct
effect
signific
increas
rate
invas
diseas
due
nonvaccin
serotyp
pneumococcu
observ
follow
vaccin
introduct
usa
howev
increas
small
rel
decreas
vaccinetyp
invas
diseas
caus
vaccin
current
licens
vaccin
prevnar
contain
serotyp
caus
sever
diseas
develop
countri
notabl
serotyp
new
conjug
vaccin
contain
serotyp
provid
optim
serotyp
coverag
countri
clinic
develop
includ
vaccin
wyeth
two
vaccin
gsk
sanofipasteur
trial
conduct
two
african
countri
use
conjug
vaccin
contain
serotyp
addit
vaccin
first
studi
south
africa
involv
subject
show
efficaci
intenttotreat
vaccin
type
invas
diseas
hivinfect
uninfect
children
respect
interestingli
studi
also
show
reduct
virusassoci
pneumonia
influenzaviru
paramyxovirus
requir
hospit
suggest
dual
infect
virus
pneumococcu
common
among
children
sever
diseas
requir
hospit
recent
publish
result
trial
gambia
show
efficaci
vaccin
type
invas
diseas
efficaci
radiolog
pneumonia
significantli
studi
also
show
reduct
mortal
vaccin
group
vaccin
tetanu
diphtheria
toxoid
protein
carrier
sanofipasteur
undergo
efficaci
trial
philippin
vaccin
unlik
develop
licensur
addit
improv
formul
gsk
conjug
vaccin
also
clinic
trial
newer
vaccin
approach
also
develop
order
provid
protect
immun
larger
number
pneumonia
serotyp
circumv
complex
manufactur
conjug
vaccin
sever
pneumococc
protein
includ
pneumolysin
pspa
pneumococc
surfac
adhesin
psaa
neuraminidas
autolysin
earli
clinic
stage
develop
piaa
piua
two
newli
identifi
lipoprotein
compon
pneumonia
iron
uptak
abc
transport
elicit
protect
immun
invas
pneumococc
diseas
mice
induct
opsonophagocytosispromot
antibodi
pspa
test
phase
trial
shown
elicit
antibodi
protect
mice
otherwis
fatal
pneumococc
infect
screen
pneumonia
genom
express
librari
human
convalesc
sera
shire
biolog
canada
id
biomed
identifi
appear
remark
conserv
bacteri
surfac
protein
abl
induc
protect
antipneumococc
antibodi
mous
model
recombin
kd
hybrid
protein
engin
fusion
part
two
gene
express
high
yield
e
coli
fusion
protein
success
test
phase
dose
rang
clinic
trial
toddler
elderli
volunt
phase
ii
clinic
studi
infant
elderli
person
initi
person
commun
vaccin
serotypeindepend
antigen
common
serotyp
pneumonia
acut
respiratori
infect
remain
common
caus
morbid
mortal
children
worldwid
also
constitut
import
caus
mortal
elderli
popul
emerg
infect
sar
lurk
risk
pandem
influenza
pose
new
threat
new
develop
field
vaccinolog
offer
real
possibl
control
problem
immun
sinc
infect
multipl
pathogen
appear
contribut
sever
diseas
prevent
one
infect
offer
possibl
morbid
reduct
respiratori
pathogen
demonstr
case
pneumococc
vaccin
viral
respiratori
infect
howev
number
obstacl
still
need
overcom
avail
effect
vaccin
limit
suppli
avail
high
price
put
reach
vulner
popul
develop
countri
sever
vaccin
face
technic
challeng
obstacl
develop
relat
intellectu
properti
right
consid
seriou
problem
acut
respiratori
infect
pose
global
urgent
need
concert
effort
overcom
obstacl
make
life
save
vaccin
avail
afford
citizen
world
